Recombinant Human SLAM Family Member 7/SLAMF7/CD319/CRACC (C-6His)

Recombinant Human SLAM Family Member 7/SLAMF7/CD319/CRACC (C-6His)

SKU: C316-10ug
Recombinant Human SLAMF7 is produced by our Mammalian expression system and the target gene encoding Ser23-Ser225 is expressed with a 6His tag at the C-terminus. Bon Opus Cat. #C316
  • Accession Number

  • Background

    SLAMF7 is a single-pass type I membrane protein and contains 1 Ig-like C2-type (immunoglobulin-like) domain. SLAMF7 is expressed in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-cell lines, or T-cell lines. Although the cytoplasmic domain of CS1 contains immunoreceptor tyrosine-based switch motifs (ITSM), which enables to recruite signaling lymphocyte activation molecule (SLAM)-associated protein (SAP/SH2D1A), it activates NK cells in the absence of a functional SAP. SLAMF7 positively regulated natural killer cell functions by a mechanism dependent on the adaptor EAT-2 but not the related adaptor SAP. However, in the absence of EAT-2, CRACC potently inhibited natural killer cell function. It was also inhibitory in T cells, which are typically devoid of EAT-2. Thus, SLAMF7 can exert activating or inhibitory influences on cells of the immune system depending on cellular context and the availability of effector proteins.
  • Expression

    Human Cells
  • Packaging

  • Formulation

    Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
  • ALTnames

    SLAM Family Member 7, CD2 Subset 1, CD2-Like Receptor-Activating Cytotoxic Cells, CRACC, Membrane Protein FOAP-12, Novel Ly9, Protein 19A, CD319, SLAMF7, CS1
  • Twitter
  • Facebook
  • LinkedIn

Terms and Conditions  I  Privacy Policy  I  Legal  I  Sitemap ©2020 by Bon Opus Biosciences, LLC.     150 Essex St, Millburn, NJ 07041, USA